Colorectal Cancer Drug Pipeline Update 2008

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

There are today more than 250 therapeutics targeting colorectal cancer, from early preclinical to marketed drugs. Colorectal Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 134 different targets. These targets are further categorized on the CD-ROM by 47 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Colorectal Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - hit more

May 2008.
More...
Price: $2,350.00 / GBP1,175.00